J. Menezes

机构：Universidade Federal da Bahia, Hospital Nossa Senhora da Conceição

发表论文 10 篇 · 总被引 88 次 · h-index 4

代表论文

• Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA (2025 · ESMO Open · 被引 31)
• 65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC (2024 · Immuno-Oncology Technology · 被引 22)
• Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis (2025 · The Oncologist · 被引 16)
• Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials (2025 · European Journal of Surgical Oncology · 被引 11)
• Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis (2025 · British Journal of Cancer · 被引 4)
• 1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA (2022 · Annals of Oncology · 被引 3)